This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved…
Article
11 months ago ●
7 mins read
An early heme-binding inhibitor of the once red-hot immunotherapy target, IDO1. Indoleamine 2,3-dioxygenase 1 (IDO1) is an extrahepatic tryptophan-metabolizing enzyme…
molecule
4 months ago ●
5 mins read
Abstract. Voxelotor, a gram-daily reversible covalent aldehyde drug, is an approved first-in-class oral drug that prevents the hemoglobin polymerization that…
Article
12 months ago ●
7 mins read
A potential next best-in-class allosteric TYK2 inhibitor exhibits strong Ph. II results for plaque psoriasis. Takeda Pharmaceuticals has announced positive…
molecule
5 months ago ●
11 mins read
The real magic happens when chemists can integrate computational models into their assay cascades, thanks to trust in their predictions.…
Article
12 months ago ●
10 mins read
The first approved CGRP receptor antagonist nasal spray for the treatment of migraine. Pfizer has announced the FDA-approval of zavegepant…
molecule
5 months ago ●
8 mins read
Load More
